Latest REMS Stories
MOUNTAIN VIEW, Calif., July 26, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will report financial results for the quarter ended June 30, 2011, on Monday, August 8, 2011, following the close of the U.S. financial markets.
MOUNTAIN VIEW, Calif., May 9, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the fiscal quarter ended March 31, 2011, and provided a business update.
TALLAHASSEE, Fla., March 14, 2011 /PRNewswire/ -- LearnSomething today announced the offering of their first Risk Evaluation and Mitigation Strategy(REMS) pharmacy training program for Abstral, an opioid sublingual tablet manufactured by ProStrakan, Inc., and indicated for the management of breakthrough pain in cancer patients. Pharmacies can now contact a LearnSomething representative to facilitate access to the training course required for enrollment in the Abstral REMS program in order to...
WILMINGTON, Del., Jan. 12 /PRNewswire/ -- More than 80 Risk Evaluation and Mitigation Strategy (REMS) plans have been approved by the Food & Drug Administration since their inception in March 2008.
WILMINGTON, Del., Dec. 3 /PRNewswire/ -- ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec.
WILMINGTON, Del., Oct.
WILMINGTON, Del., Aug.
WILMINGTON, Del., July 13 /PRNewswire/ -- ParagonRx, a Delaware-based company which specializes in programs for the appropriate use of medications, has launched a new website - www.paragonrx.com - that includes a "REMS Hub" for pharmaceutical and biotech companies needing information and assistance in complying with new FDA requirements to ensure the medical benefits of a drug outweigh its risks and dangerous side effects."REMS, or Risk Evaluation and Mitigation Strategy, requires a whole new...
- Withering but not falling off, as a blossom that persists on a twig after flowering.